1 / 27

24 VITILIGO VERSUS HYPERPIGMENTATION

24 VITILIGO VERSUS HYPERPIGMENTATION. VITILIGO-30% AQUIRED THYROID PATOLOGY MOSTLY THYROIDITIS HASHIMOTO AUTOIMMUNE DISEASE-DM PERNICIOUS ANEMIA ADDISON DISEASE- HYPERPIGMENTATION. 25. DM-BP BP-120/80 ACE TARGET-CHF CRF. 26. Hypercalcemia+malignancy 80%-MTS-bone destruction

ingo
Download Presentation

24 VITILIGO VERSUS HYPERPIGMENTATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 24VITILIGO VERSUS HYPERPIGMENTATION VITILIGO-30% AQUIRED THYROID PATOLOGY MOSTLY THYROIDITIS HASHIMOTO AUTOIMMUNE DISEASE-DM PERNICIOUS ANEMIA ADDISON DISEASE- HYPERPIGMENTATION

  2. 25 DM-BP BP-120/80 ACE TARGET-CHF CRF

  3. 26 • Hypercalcemia+malignancy • 80%-MTS-bone destruction • 20%-PTH like substation • Most-ca of breast lung renal • MM-lyticmts-hypercalcemia • Most-paraneoplastycsyndrom • Secondary hyperparathyroidism-hypocalcemia-hypephosphatemia-high pth

  4. 27 • No family history of graves or hashimoto for ca of thyroid • Solid nodules more malignant than cystyc • Nodule hyperactive non malignant • 70% pappilary cancer 15% follicular cancer 5% anaplastic 5% lymphoma • Medullary carcinoma-0,5% • Men 2-medullary cancer+pheochromacytoma Men 1-hyperparahyroidism+prolactinoma+glucagonoma • Calcitonin-marker of thyroid cancer threatment

  5. Dopamine lower prolactine level28 • Bromocriptin/dopamine agonist/ for microadenomathreatment • Neuroleptics = high prolactine • Only high doses of estrogen=high prolactine • Microadenoma less 1 smmacroadenoma more then 1 sm • Threatment-bromocriptine’surgery’radiotherapy’pergolide

  6. Hyperthyroidism • More female • Graves d.-most common 90% before40 • Ophtalmopathy,pretibialmixedema after therapy,vitiligo,gynecomasty,onycholysis • thyroid enlarged +bruits • Reversible cardiomyopathy • Toxic multinodular goiter-elderly,long standing goiter,cardiovascularsymptoms,weightloss,constipation,

  7. HYPERTHYROIDISM • Single hot-toxic nodule • T3 high t4 high,threatmentelthroxinanr then surgery • Transient hyperthyroidism-subacute or After viral infection esr high ,zahvatjodanizkij- Lymphatyc Hashimoto-female middle age antiperoxidaseab Subacutepospartumthyroidit–transient.mild,like hashimoto Subclinical hyperthyroidism-low tsh normal t4 t3

  8. Hypethyroidism • Goiterogenic medications-jodcontrast,amiodaron,lithium • Diagnostic-thyroid scan • Lab-hypercalcemia,anemia,lymphocytosis,GOT GPT high • Treatment-bb ,methimasol,ptu • Methimasol-agranulocitosis • Elderly-ablation with radioactive jod,young-surgery • Side effects-hypothyroidism,laryngeoparalysis • Treatment of oftalmopathy-high doses iv steroids

  9. hypothyroidism • Female,mosthashimoto ,primary –thyroid function secondary-hypophisis function • Severe-mixedema+cts+amenorrhea+hypotension • Hdl-decrease ldl-increase • Anemia normo-normo • B12 def anemia • Elthroxin-dexa • Cabg-chf-severe cihd-not replacement of elthroxin

  10. Diabetes insipidus • Plasma osmolarity more 290—adh secretion—reabsorbtion of water rise--sensitivity H2O • rise in distal canals • Water diuresis/di/ versus solution diuresis/dm/ • Water diuresis-low osmolarity of urine • Nephrogenicdi-lithium or amphotericin • Di-high osmolarity of plasma

  11. Addison disease • Primary adrenocortical insufficiency • 100%weakness,weight loss,hypotonia, • Na low k high bun high ca high acth high • Hyperpigmentation • Causes-tb cancer • Therapy if acute-iv hydrocortison

  12. Conn’s syndrom • Primary hyperaldosteronism • Mineralcorticoids excess • Weakness • Hypertension • Adenoma or hyperplasia • Na high k low renin low • High kalium in urine • Treatment-surgery ,spironolactone

  13. hypoglycemia • Whipple triade-glucose low 50 +neuroglycopenia/confusion,letargy,blurred vision/ +adrenogenic stimulation-anxiety,sweating,palpitation/+symptoms dissapearance with glucose level Normalization Thrue reactive hypoglycemia-after gastric surgery-not demping syndrome Non-isled cell tumors-hepatoma-insulin low c-peptide low Insulinoma-insuline high c-peptide high

  14. DM • DCCT-DIABETES CONTROL AND DIABETES COMPLICATION STUDY-TYPE 1-GLUCOSE CONTROLE LOWER MICROVASCULAR COMLICATIONS • UKPDS-UNATED KINGDOM PROSPECTIVE DIABETES STUDY GLUCOSE CONTROLE LOWER NEPHROPATHY AND RETINOPATHY • IGT -5% EVERY EAR-DM • DRUGS-THIAZIDES BB ZYPREXA • A-MIMETICS • FENITOIN • LADA-LATE AUTOIMUNE DIABETES OF ADULTS-AB TO INSULIN

  15. Risk factors for dm • Недостаточность упражнений • Этнические –азиаты.эфиопы • Вес при рождении более 4 кг • Igtifg • Pregnancy diabetes • Pco • Htn • Hdl<35 tg>250

  16. Metabolic syndromx-syndrom • Fg>110 • Abdominal obesiry -102\88 • Tg>150 • hdl<40 • htn >130\85 • 3 criterions

  17. ACCORD –Action of Control Cardiovascular Risk in DM • No significant decrease in cardiovascular events with intensive glucose control • Trial ended after 3.5 years because of significant increase in death in intensive glucose control group

  18. ADVANCE –Action in Diabetes and vascular disease • Published 12.06.08 NEJ of Medicine • 11 .400 patients with DM type 2 • There was no evidence that intensive glucose control reduce new retinopathy ,nephropathy,polyneuropathy or risk of major cardiovascular events

  19. Reduce Hb A1C to 1% • Microvascular complication reduce to 37% • MI risk less 14% • All diabetes related complications 21% • Amputation 47%

  20. VADT INVESTIGATION- vascular complications in Veteran with type 2 DM • Median Hb A1C in standard group 8.4% • Median Hb A1C in intensive group 6.9% • 1791 military veterans • Median follow up 5.6 years • No significant difference in retinopathy, neuropathy, nephropathy and major cardiovascular events

  21. Сульфонуреа • Глибенкламид – Глюбен - 5 мг • Глипизид - Глюко Райт – 5 мг • Глимеперид – Амарил -1, 2. 3 мг

  22. Бигуанид • Глюкофаж, Мерформин,Глюфор 850мг

  23. Репаглинид • Новонорм 0.5, 1, 2 мг

  24. Инкретины • GLP 1- Glucagon Like Peptide выделяется В тонком кишечнике Л клетками и стимулирует выброс инсулина на пищу • Подавляет секрецию глюкагона • Замедляет опорожнение желудка • Вызывает чувство сытости , меньше потребность в пище -уменьшает апоптоз в бета клетках

  25. Баета – эксенатид и Виктоза-липаглутид • Иньекции баеты дважды в день Первый месяц 5 мг дважды в день и далее по 10 мг Перерыв между первым и вторым уколом не менее 6 часов - Виктоза 6 мг – раз в день

  26. GPP4 – энзим ди пептидил пептидаза 4 разрушает GLP 1 • GPP4 inhibitor – sitagliptin- Januvia Таблетки 25, 50, 100 мг • И 50 мг при почечной недостаточности • Metformin + Januvia = Januet Metformin500/50 , 850/50 , 1000/50

  27. Розиглитазоны и пиоглитазоны • Авандия, Россини 4, 8 мг –розиглитазон • Новопиоглитазон

More Related